OncoZenge AB (publ) (ONCOZ.ST)
- Previous Close
4.5550 - Open
4.5500 - Bid 4.6050 x --
- Ask 4.8000 x --
- Day's Range
4.5500 - 4.7500 - 52 Week Range
2.8000 - 12.1000 - Volume
9,102 - Avg. Volume
40,772 - Market Cap (intraday)
55.638M - Beta (5Y Monthly) 1.33
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.50
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.
oncozenge.comRecent News: ONCOZ.ST
View MorePerformance Overview: ONCOZ.ST
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONCOZ.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONCOZ.ST
View MoreValuation Measures
Market Cap
53.35M
Enterprise Value
33.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.36
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.17%
Return on Equity (ttm)
-60.77%
Revenue (ttm)
1k
Net Income Avi to Common (ttm)
-8.69M
Diluted EPS (ttm)
-0.7400
Balance Sheet and Cash Flow
Total Cash (mrq)
3.86M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.5M